

May 13, 2016

Phase 2b Data Release Next Week; Reiterate Buy

Stock Data		05/11/2016		
Rating		Buy		
Price		\$6.80		
Exchange		NASDAQ		
Price Target		\$25.00		
52-Week High		\$10.74		
52-Week Low		\$4.15		
Enterprise Value (MM)		\$88		
Market Cap (MM)		\$89		
Public Market Float (MM)		9.7		
Shares Outstanding (MM)		13.1		
3 Month Avg Volume		55,587		
Short Interest (MM)		0.53		
Balance Sheet Metrics				
Cash (MM)		\$25.60		
Total Debt (MM)		\$0.00		
Total Cash/Share		\$1.95		
Book Value/Share		\$2.50		
EPS Diluted				
Full Year - Aug	2015A	2016E	2017E	
1Q	(0.19)	(0.21)A	--	
2Q	(0.16)	(0.22)	--	
3Q	(0.15)	(0.21)	--	
4Q	(0.18)	(0.22)	--	
FY	(0.67)	(0.85)	(1.18)	

Phase 2b data release next week. We are herewith reminding investors that Oramed could release top-line data next week from the Phase 2b trial of its lead oral insulin candidate, ORMD-0801. The data remain blinded at this time, however, and accordingly we would view recent weakness in the stock as a potential buying opportunity. In our opinion, positive Phase 2b data would constitute a transformative event for the company. The firm is also conducting a Phase 1b trial with its second pipeline candidate, ORMD-0901 and expects data imminently; this could pave the way for initiation of a Phase 2b trial with ORMD-0901 later in the year. Oramed also closed 2015 with roughly \$40M in cash, which we believe should be sufficient to fund operations for at least the next two years. Accordingly, we reiterate our Buy rating and 12-month price target of \$25.00 per share.

China licensing deal may herald further business development. In our view, Oramed's recently-completed licensing deal involving China rights to ORMD-0801 could be a harbinger of additional licensing transactions. The firm might, for example, elect to pursue other regional partnerships with other entities possessing geographically specialized commercial expertise. We believe that the valuation of the China rights to ORMD-0801 at \$50M plus royalties on net sales provides a solid benchmark for future transactions.

Discounted technology platform. Oramed currently trades at an enterprise value well under \$100M, while the global diabetes market may exceed \$40B by 2018. In our view, positive Phase 2b data with ORMD-0801 could make this oral insulin candidate the subject of an ex-China global licensing transaction or catalyze the acquisition of Oramed in calendar 2016.

Valuation methodology, risks and uncertainties. Factoring in a 12% discount rate, a 60% probability of success for ORMD-0801, and peak annual sales of \$2.1B (on which we project double-digit percentage royalties), we derive a total rNPV of \$130M. We add to this the value from Oramed's pipeline, mainly ORMD-0901, to which we ascribe a valuation of \$180M, to derive a total firm value of \$357M. This translates into a price objective of \$25.00 per share, assuming net cash of ~\$56M and ~14.9M fully-diluted shares outstanding as of end-fiscal 2016. Risks to our price target include, but are not limited to: (i) adverse results from the Phase 2b trial of ORMD-0801; (ii) delays and potential negative data from other studies, including the Phase 1b trial of ORMD-0901; and (iii) negative regulatory actions.



Table 1: Oramed Pharmaceuticals, Inc. (ORMP)—Historical Income Statements, Financial Projections

FY end August 31

\$ in thousands, except per share data

	2015A					2015A	2016E				2016E	2017E	2018E
	2014A	1QA	2QA	3QA	4QA		1QA	2QE	3QE	4QE			
Revenue													
Product revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and other	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Expenses													
Cost of product and service revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Research & development	3,277	1,302	1,136	915	1,428	4,781	1,901	1,800	1,700	1,600	7,001	9,100	12,200
Selling and marketing	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative	2,629	600	538	719	745	2,602	548	1,000	1,300	1,500	4,348	7,600	10,400
Total expenses	5,906	1,902	1,674	1,634	2,173	7,383	2,449	2,800	3,000	3,100	11,349	16,700	22,600
Gain (loss) from operations	(5,906)	(1,902)	(1,674)	(1,634)	(2,173)	(7,383)	(2,449)	(2,800)	(3,000)	(3,100)	(11,349)	(16,700)	(22,600)
Other income/expense													
Financial income	225	27	38	51	52	168	76	50	85	75	286	246	318
Financial expense	(11)	(21)	(1)	-	4	(18)	(17)	-	-	-	(17)	(120)	(120)
Impairment of available-for-sale securities	-	-	-	-	106	106	(406)	-	-	-	-	-	-
Total investment income and other	214	6	37	51	162	256	(347)	50	85	75	269	126	198
Loss before provision for income taxes	(5,692)	(1,896)	(1,637)	(1,583)	(2,011)	(7,127)	(2,796)	(2,750)	(2,915)	(3,025)	(11,080)	(16,574)	(22,402)
Deferred income tax benefit	(4)	-	-	-	1	1	1	1	1	1	4	4	4
Net loss/income	(5,696)	(1,896)	(1,637)	(1,583)	(2,010)	(7,126)	(2,795)	(2,749)	(2,914)	(3,024)	(11,076)	(16,570)	(22,398)
Net loss per share (basic)	(0.62)	(0.19)	(0.16)	(0.15)	(0.18)	(0.67)	(0.21)	(0.22)	(0.21)	(0.22)	(0.85)	(1.18)	(1.53)
Net loss per share (diluted)	(0.62)	(0.19)	(0.16)	(0.15)	(0.18)	(0.67)	(0.21)	(0.22)	(0.21)	(0.22)	(0.85)	(1.18)	(1.53)
Weighted average number of shares outstanding (basic)	9,244	10,142	10,482	10,828	11,200	10,663	11,573	12,729	13,881	13,931	13,028	14,056	14,631
Weighted average number of shares outstanding (diluted)	9,244	10,142	10,482	10,828	11,200	10,663	11,573	12,729	13,881	13,931	13,028	14,056	14,631

Source: Company reports and Rodman & Renshaw estimates.

Important Disclaimers

Rodman & Renshaw is a unit of H.C. Wainwright & Co., LLC. Research is created and distributed by and securities are offered through H.C. Wainwright & Co. LLC, (the "Firm") Member FINRA/SIPC, which conducts certain research activities under the name Rodman & Renshaw.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

RETURN ASSESSMENT

Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the common stock of companies within the same sector.

Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index comprised of all the common stock of companies within the same sector.

Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all the common stock of companies within the same sector.



Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

Distribution of Ratings Table				
Ratings	Count	Percent	IB Service/Past 12 Months	
			Count	Percent
Buy	182	98.38%	50	27.47%
Neutral	3	1.62%	2	66.67%
Sell	0	0.00%	0	0.00%
Under Review	0	0.00%	0	0.00%
Total	185	100%	52	28.11%

I, Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of (including, without limitation, any option, right, warrant, future, long or short position).

As of May 30, 2016 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Oramed Pharmaceuticals, Inc..

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did receive compensation from Oramed Pharmaceuticals, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in Oramed Pharmaceuticals, Inc. as of the date of this research report.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co, LLC. Additional information available upon request.